TY - JOUR
T1 - Decreased expression of caveolin 1 in patients with systemic sclerosis: Crucial role in the pathogenesis of tissue fibrosis
AU - Del Galdo, Francesco
AU - Sotgia, Federica
AU - De Almeida, Cecilia J.
AU - Jasmin, Jean Francois
AU - Musick, Megan
AU - Lisanti, Michael P.
AU - Jiménez, Sergio A.
N1 - R01 AR055660-02, NIAMS NIH HHS, United StatesR01-AR-019616, NIAMS NIH HHS, United StatesR01-CA-080250, NCI NIH HHS, United States
PY - 2008/9
Y1 - 2008/9
N2 - Objective. Recent studies have implicated caveolin 1 in the regulation of transforming growth factor β (TGFβ) downstream signaling. Given the crucial role of TGFβ in the pathogenesis of systemic sclerosis (SSc), we sought to determine whether caveolin 1 is also involved in the pathogenesis of tissue fibrosis in SSc. We analyzed the expression of CAV1 in affected SSc tissues, studied the effects of lack of expression of CAV1 in vitro and in vivo, and analyzed the effects of restoration of caveolin 1 function on the fibrotic phenotype of SSc fibroblasts in vitro. Methods. CAV1 expression in tissues was analyzed by immunofluorescence and confocal microscopy. The extent of tissue fibrosis in Cav1-knockout mice was assessed by histologic/histochemical analyses and quantified by hydroxyproline assays. Cav1-null and SSc fibroblast phenotypes and protein production were analyzed by real-time polymerase chain reaction, immunofluorescence, Western blot, and multiplexed enzymelinked immunosorbent assay techniques. The effects of restoration of caveolin 1 function in SSc fibroblasts in vitro were also examined using a cell-permeable recombinant CAV1 peptide. Results. CAV1 was markedly decreased in the affected lungs and skin of SSc patients. Cav1-knockout mice developed pulmonary and skin fibrosis. Down-regulation of caveolin 1 was maintained in cultured SSc fibroblasts, and restoration of caveolin 1 function in vitro normalized their phenotype and abrogated TGFβ stimulation through inhibition of Smad3 activation. Conclusion. Caveolin 1 appears to participate in the pathogenesis of tissue fibrosis in SSc. Restoration of caveolin 1 function by treatment with a cell-permeable peptide corresponding to the CAV1 scaffolding domain may be a novel therapeutic approach in SSc. © 2008, American College of Rheumatology.
AB - Objective. Recent studies have implicated caveolin 1 in the regulation of transforming growth factor β (TGFβ) downstream signaling. Given the crucial role of TGFβ in the pathogenesis of systemic sclerosis (SSc), we sought to determine whether caveolin 1 is also involved in the pathogenesis of tissue fibrosis in SSc. We analyzed the expression of CAV1 in affected SSc tissues, studied the effects of lack of expression of CAV1 in vitro and in vivo, and analyzed the effects of restoration of caveolin 1 function on the fibrotic phenotype of SSc fibroblasts in vitro. Methods. CAV1 expression in tissues was analyzed by immunofluorescence and confocal microscopy. The extent of tissue fibrosis in Cav1-knockout mice was assessed by histologic/histochemical analyses and quantified by hydroxyproline assays. Cav1-null and SSc fibroblast phenotypes and protein production were analyzed by real-time polymerase chain reaction, immunofluorescence, Western blot, and multiplexed enzymelinked immunosorbent assay techniques. The effects of restoration of caveolin 1 function in SSc fibroblasts in vitro were also examined using a cell-permeable recombinant CAV1 peptide. Results. CAV1 was markedly decreased in the affected lungs and skin of SSc patients. Cav1-knockout mice developed pulmonary and skin fibrosis. Down-regulation of caveolin 1 was maintained in cultured SSc fibroblasts, and restoration of caveolin 1 function in vitro normalized their phenotype and abrogated TGFβ stimulation through inhibition of Smad3 activation. Conclusion. Caveolin 1 appears to participate in the pathogenesis of tissue fibrosis in SSc. Restoration of caveolin 1 function by treatment with a cell-permeable peptide corresponding to the CAV1 scaffolding domain may be a novel therapeutic approach in SSc. © 2008, American College of Rheumatology.
U2 - 10.1002/art.23791
DO - 10.1002/art.23791
M3 - Article
C2 - 18759267
SN - 2151-464X
VL - 58
SP - 2854
EP - 2865
JO - Arthritis Care & Research
JF - Arthritis Care & Research
IS - 9
ER -